Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective

December 12, 2014

The United Kingdom Drug Strategy emphasises recovery as a key focus in the treatment of drug dependence. A framework for recovery is defined in the Recovery-Orientated Drug Treatment report, written by an expert working group, and comprises four key phases: engagement and stabilisation, including the establishment of treatment goals; preparation for change, involving engagement in […]

Read the full article →

Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence A Randomized Clinical Trial

December 3, 2014

ImportancePrescription opioid dependence is increasing and creates a significant public health burden, but primary care physicians lack evidence-based guidelines to decide between tapering doses followed by discontinuation of buprenorphine hydrochloride and naloxone hydrochloride therapy (hereinafter referred to as buprenorphine therapy) or ongoing maintenance therapy.ObjectiveTo determine the efficacy of buprenorphine taper vs ongoing maintenance therapy in […]

Read the full article →

BUPRENORPHINE AND NALOXONE Tablet [Teva Pharmaceuticals USA Inc]

December 3, 2014

Updated Date: Dec 1, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.

December 3, 2014

Authors: Balhara YP PMID: 24380101 [PubMed – indexed for MEDLINE] (Source: Journal of Opioid Management)

Read the full article →

Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.

December 3, 2014

CONCLUSION: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing. PMID: 23264315 [PubMed – indexed for MEDLINE] (Source: Journal of Opioid Management) MedWorm Sponsor Message: Directory of the […]

Read the full article →

Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.

November 30, 2014

CONCLUSIONS: Treatment with higher doses of buprenorphine/naloxone was associated with a longer time to treatment discontinuation, less resource use, and lower total medical costs despite higher pharmacy acquisition cost. PMID: 25295655 [PubMed – in process] (Source: Postgraduate Medicine) MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space…

Read the full article →

UC tests whether iPads can help curb drug abuse

November 27, 2014

Researchers at the University of Cincinnati have begun studying whether iPads with facial recognition software can verify that patients are taking medications prescribed to combat drug abuse. The software from New York-based AiCure is designed to confirm that a patient ingested the right medication at the right time. The clinical study involving 140 patients focuses […]

Read the full article →

Table of Contents

November 22, 2014

Abstract For Teens with Opioid Use Disorders, Bupe Better than Detox‐Rehab‐Relapse Providers Should Use Insurance Mandate in Pennsylvania DEA Investigates NFL Teams for Painkiller Abuse Medicaid Expansion Enabled More Recovery Services in Ohio For Suboxone, Goodbye Reckitt, Hello Spinoff Indivior Coming up (Source: Alcoholism and Drug Abuse Weekly) MedWorm Sponsor Message: MedWorm Search is coming […]

Read the full article →

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

November 14, 2014

Authors: Yokell MA, Zaller ND, Green TC, Rich JD Abstract The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and […]

Read the full article →

Buprenorphine and buprenorphine/naloxone intoxication in children – how strong is the risk?

November 14, 2014

Authors: Soyka M Abstract Opioid maintenance therapy with methadone or buprenorphine is an established and first-line treatment for opioid dependence. Risk of diversion and toxicity of opioid prescription drugs, including buprenorphine, causes significant concerns. This is particularly the case in the United States, where the number of related emergency visits is increasing, especially in children. […]

Read the full article →

← Previous Entries

Next Entries →